SNAC has been reviewed by the FDA as part of the approval of Rybelsus and the Wegovy pill, and both medications remain FDA-approved. A 2026 animal study raised new questions about long-term effects on gut bacteria and inflammation markers, and those questions deserve more research in people.

Does injectable Wegovy or Ozempic contain SNAC?

No. SNAC is only used in the oral forms of semaglutide, which are Rybelsus and the Wegovy pill. Injectable GLP-1 medications do not need it.

Should I stop taking my oral GLP-1 medication because of this study?

No, not without talking to your provider. The study was done in rats, not people, and the FDA has not taken any new action on these medications. Stopping a GLP-1 medication suddenly can affect your weight management and, if you have diabetes, your blood sugar.

Does Foundayo contain SNAC?

No. Foundayo (orforglipron) is a small molecule GLP-1 medication that is chemically stable in the stomach and does not need an absorption helper like SNAC.

How do I know if my oral GLP-1 medication is working for me?

Your provider will track your weight, side effects, and any lab markers that apply to your situation. If you have questions about whether your current medication is still the right fit, bring them to your next visit.

Is this the same as a recall?

No. A recall is a formal action the FDA or the manufacturer takes when a product has a serious problem. This study is published research, not a recall, and no recall has been announced for oral semaglutide because of it.

What Is SNAC? The Ingredient in GLP-1 Pills

One-sentence direct answer: SNAC is an inactive ingredient added to oral semaglutide pills like the Wegovy pill and Rybelsus that helps the medication survive stomach acid long enough to get absorbed into your bloodstream, and a new 2026 animal study has raised fresh questions about whether daily SNAC exposure might also affect gut bacteria and inflammation markers in ways that deserve more research (ScienceDirect).

Who This Helps

This one is for anyone who saw a headline about a "hidden ingredient in Ozempic pills" and wants a clear-eyed explanation. Not a scare post. Not a dismissal. A look at what SNAC is, what the new study actually found, what it did not find, and what it means for people currently on an oral GLP-1 medication.

What SNAC Stands For and What It Does

SNAC is short for sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, also called salcaprozate sodium (PubMed Central). It is an absorption helper, a small chaperone molecule that walks the active drug through a tough neighborhood.

Oral semaglutide medications contain semaglutide, which is a peptide. Peptides are short chains of amino acids, and the stomach is designed to break them down on contact. SNAC temporarily raises the pH right around the tablet, protects the semaglutide, and helps it cross the stomach lining into the bloodstream (PubMed Central). Without SNAC, oral semaglutide would not work. That is why the Wegovy pill and Rybelsus come with such specific instructions: empty stomach, small sip of water, wait 30 minutes. The SNAC has one shot to do its job, and the conditions in the stomach matter (Wegovy Prescribing Information).

Which Medications Contain SNAC

SNAC is found in:

Rybelsus, the oral semaglutide approved for type 2 diabetes
The Wegovy pill, the oral semaglutide approved for chronic weight management

It is not found in injectable GLP-1 medications. Ozempic, injectable Wegovy, Mounjaro, Zepbound, and the new Foundayo pill do not contain SNAC.

What the New Study Actually Found

In February 2026, researchers published a study in the Journal of Controlled Release looking at what happens to gut bacteria and inflammation markers in rats given daily SNAC, daily semaglutide, or both, over 21 days (ScienceDirect).

The key findings in the rats were:

SNAC changed the balance of gut bacteria, specifically reducing two families of bacteria called Muribaculaceae and Bacteroidaceae. These are bacteria that help break down fiber and keep things running smoothly down there (ScienceDirect).
The rats had lower levels of butyrate, a short-chain fatty acid that gut bacteria produce, which plays a role in gut lining health.
Some inflammation markers in the blood went up, including one called TNF-alpha, while levels of a brain protein called BDNF went down.

The researchers used careful language. They called these "associations," not proof of harm. They wrote clearly that the findings deserve follow-up studies in humans before anyone draws firm conclusions.

What the Study Did Not Show

This is the part that often gets buried in headlines, and it really matters. The study was done in healthy rats, not people. It did not show:

That people taking the Wegovy pill or Rybelsus are being harmed
That the oral GLP-1 medications have been recalled or flagged by the FDA
That the benefits of oral semaglutide do not outweigh the risks for people who need it

The FDA has not issued any new safety action on oral semaglutide products based on this study, and both medications remain FDA-approved for their intended uses (FDA).

What this means for you: Animal studies are often the first step in raising a research question. They are not the final word. A finding in rats does not automatically translate to humans, but it is worth keeping an eye on as follow-up research comes out.

Why This Matters for People on Oral GLP-1 Medications

For anyone taking the Wegovy pill or Rybelsus, the steady read is this. The medication has a real job to do. If a provider prescribed it and it is being tolerated well, one animal study is not a reason to stop taking it without medical guidance. Stopping a GLP-1 medication suddenly can affect weight management and, for people with diabetes, blood sugar control.

This study is also a fair thing to bring up at the next visit. A useful conversation might sound like: "I read about a new study on SNAC and gut bacteria. I know it was done in rats and it is not a warning. Can we talk about how my medication is working for me and whether I should keep an eye on anything?" That is a reasonable question, and a good provider will welcome it.

For background before starting or adjusting a GLP-1 medication, see what to know before your first GLP-1 dose and what questions a provider will ask before prescribing a GLP-1.

How This Fits Into the Bigger GLP-1 Picture

The GLP-1 category is still young by medical standards. Every year brings new trials, new approvals, and new research on how these medications behave in the body over the long term. That is true for every medication in the category, not just oral semaglutide.

At GLP Winner, our view is that new research is information, not a crisis. The goal is to stay informed without jumping to conclusions, and to make decisions with a provider based on an individual medical picture. For how other GLP-1 news has unfolded over the past year, the GLP-1 insights library has more.

Final Takeaway

SNAC is an absorption helper in oral semaglutide pills that does a real and necessary job. A new animal study in 2026 raised questions about whether long-term SNAC exposure might also affect gut bacteria and inflammation markers, and those findings deserve more research in people. That is not the same as a safety warning. For anyone on an oral GLP-1 medication that is working, this study is not a reason to stop. It is a reason to bring the topic up at the next provider visit.

If you enjoy posts like these, you can subscribe to receive newsletter updates.

What Is SNAC? A Key Ingredient in Oral GLP-1 Pills

Who This Helps

What SNAC Stands For and What It Does

Which Medications Contain SNAC

What the New Study Actually Found

What the Study Did Not Show

Why This Matters for People on Oral GLP-1 Medications

How This Fits Into the Bigger GLP-1 Picture

Final Takeaway

Sources

Keep Reading

FDA Approves Foundayo: The New GLP-1 Pill Explained

Pill Versions of GLP-1s: Are You Missing Out If You Skip the Needles?

The Wegovy Pill Is Live: What It Means For You In 2026

What Questions Will a Provider Ask Before Prescribing a GLP-1?

Categories

Curated by